Abstract
Trastuzumab has been clearly demonstrated to improve overall survival for both early and metastatic HER2 positive breast cancer. However, despite the improved clinical outcomes seen with the addition of HER2 targeted therapy to conventional cytotoxic agents, the response rates remain between 30-55% and the majority of patients with advanced breast cancer experience disease progression within 1 year. In this review article, we provide a summary of the key mechanisms of resistance to trastuzumab, including the truncated form of HER2 (p95HER2), compensatory up-regulation of receptor cross-talk, genetic mutations and aberrancies in molecular pathways that allow tumor cells to evade cell cycle regulations. In recent years, treatment options for patients with trastuzumab-resistant disease have been developed and approved, including lapatinib and T-DM1. Ongoing research is evaluating multiple other therapeutic regimens that include novel HER2- targeting agents for the treatment of resistant disease. We will review these newer therapies as well as the scientific rationale behind treatment regimens that have been studied in patients with trastuzumab-resistant HER2 positive breast cancer.
Keywords: Breast cancer, HER2, lapatinib, neratinib, metastatic, T-DM1, trastuzumab resistance.
Current Cancer Therapy Reviews
Title:Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options
Volume: 11 Issue: 4
Author(s): Sangmee Bae and Sara Hurvitz
Affiliation:
Keywords: Breast cancer, HER2, lapatinib, neratinib, metastatic, T-DM1, trastuzumab resistance.
Abstract: Trastuzumab has been clearly demonstrated to improve overall survival for both early and metastatic HER2 positive breast cancer. However, despite the improved clinical outcomes seen with the addition of HER2 targeted therapy to conventional cytotoxic agents, the response rates remain between 30-55% and the majority of patients with advanced breast cancer experience disease progression within 1 year. In this review article, we provide a summary of the key mechanisms of resistance to trastuzumab, including the truncated form of HER2 (p95HER2), compensatory up-regulation of receptor cross-talk, genetic mutations and aberrancies in molecular pathways that allow tumor cells to evade cell cycle regulations. In recent years, treatment options for patients with trastuzumab-resistant disease have been developed and approved, including lapatinib and T-DM1. Ongoing research is evaluating multiple other therapeutic regimens that include novel HER2- targeting agents for the treatment of resistant disease. We will review these newer therapies as well as the scientific rationale behind treatment regimens that have been studied in patients with trastuzumab-resistant HER2 positive breast cancer.
Export Options
About this article
Cite this article as:
Bae Sangmee and Hurvitz Sara, Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options, Current Cancer Therapy Reviews 2015; 11 (4) . https://dx.doi.org/10.2174/1573394712666151119213606
DOI https://dx.doi.org/10.2174/1573394712666151119213606 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Emerging Role of the Histamine H4 Receptor in Anti-inflammatory Therapy
Current Topics in Medicinal Chemistry miRNA Functions in Arthritis
Current Rheumatology Reviews Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity
Current Medicinal Chemistry Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Small Molecule Inhibitors Targeting Key Proteins in the DNA Damage Response for Cancer Therapy
Current Medicinal Chemistry Nanoparticle-Based Drugs: A Potential Armamentarium of Effective Anti-Cancer Therapies
Current Drug Metabolism Exosome-Encapsulated microRNAs as Potential Circulating Biomarkers in Colon Cancer
Current Pharmaceutical Design Malignant Pleural Effusion Evaluation and Management
Current Respiratory Medicine Reviews Histamine in Immune Regulation: Possible Roles in Autoimmune Demyelinating Disease of the Central Nervous System
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Targeted Approaches to Triple-Negative Breast Cancer: Current Practice and Future Directions
Current Medicinal Chemistry The mTOR Signaling Pathway is an Emerging Therapeutic Target in Multiple Myeloma
Current Pharmaceutical Design Graphical Abstracts
Current Drug Delivery Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Curcumin has Bright Prospects for the Treatment of Inflammatory Bowel Disease
Current Pharmaceutical Design Electrochemical Nano-biosensors as Novel Approach for the Detection of Lung Cancer-related MicroRNAs
Current Molecular Medicine Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Role of Polymorphisms of FAM13A, PHLDB1, and CYP24A1 in Breast Cancer Risk
Current Molecular Medicine Editorial (Thematic Issue: Advances with microRNAs in Tumorigenesis and Cancer Therapy)
Current Pharmaceutical Design Recent Advances in the Probe Development of Technetium-99m Molecular Imaging Agents
Current Organic Synthesis